PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTC: MDXXF) announced that it has contracted with a third-party logistics company specializing in pharmaceutical products to act as its US clinical trial distribution partner. PharmAla makes novel MDXX class molecules including its LaNeo MDMA.
However, the name of PharmAla’s logistics partner is…
Please login to read all 376 words.
